Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. - Wikidata - awgldk - TriplyDB

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

http://www.wikidata.org/entity/Q37570408

about

Nomograms in oncology: more than meets the eye Phase I trials of antitumour agents: fundamental concepts Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems.Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.A Clinical Prediction Model to Assess Risk for Chemotherapy-Related Hospitalization in Patients Initiating Palliative Chemotherapy.A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.Prognostication of Survival in Patients With Advanced Cancer: Predicting the Unpredictable?Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies The role of age on dose-limiting toxicities in phase I dose-escalation trials.Pharmacological treatment for uterine leiomyosarcomas.Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.Relationship between phase I study duration and symptom burden.

P2860

Q26830260-298AC8C6-DEC2-4044-9EDF-E9331A29F50B Q26865346-4ED047CA-6DB4-4D84-A5C2-FD28CAEBFCBB Q33656484-84EAFF3A-A9CA-455D-B2E9-0AFE86A738E4 Q33822083-1FAE9608-61E9-42AB-AEF1-F60E694EDC6D Q36076727-186B3493-992F-47B3-9B95-286172BC4D6C Q36372816-8C6197F0-3EAD-49C8-8284-A83AB133E222 Q36478194-97A6C575-EDC7-43FD-BEE4-4F49D1BC6962 Q36626638-33AF4D4D-04F5-42B1-AAF0-353410C04C56 Q36871155-A10D68D1-6104-43E6-9573-E7450A73FC41 Q37166427-650DF317-FC34-4914-90FE-67234E690F72 Q37552648-238CADA5-2910-48E7-AD86-EB5684632A80 Q38270671-D9257D4C-9EEE-4871-9D41-0D270DD1D92E Q38843090-2048E397-D4DB-41E3-A22A-965837E566C4 Q38907890-143873B0-BF83-4510-9EFB-7878F0696AC0 Q38924049-0B09F417-FBE3-4350-95AC-264F1713D4BB Q49589187-3CA6B884-D4EF-4D0D-8A34-6D7DBC7C5398

P2860

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

http://www.wikidata.org/entity/Q37570408

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

@en

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

@nl

type

label

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

@en

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

@nl

prefLabel

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

@en

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

@nl

P1433

Q37570408-FD24F7E8-2B12-4A18-937B-C36ECF566F55

P1476

Q37570408-A99AC718-0DEA-4AA0-9D14-544F74EA476A

P2093

Q37570408-14E697D9-E5CC-428A-9B22-6594DC325CEA

Q37570408-20CAB0DB-B26E-4427-846F-66E0ED57D695

Q37570408-53D0E2B9-4B6E-447C-876D-86D9A905CFDC

Q37570408-55F7C48B-BDB7-4886-8937-C95661154076

Q37570408-87198DA2-6AC5-43A9-AA37-7077D1F3EE37

Q37570408-87E8BF39-8787-4789-85C2-A93D2C791207

Q37570408-98F09C06-D49E-4B1E-9959-09EE38C68795

Q37570408-DB11F840-C0B8-4691-8E3D-5924CEB478A2

Q37570408-EDC3E3F1-AD58-4FFF-B5FD-0B174BE5D50C

P2860

Q37570408-269BC6D9-B686-462A-BE3F-8A672B95D28F

Q37570408-2A8AE960-87F1-4A89-98C7-E68215AD9410

Q37570408-5D420183-A262-4F91-9718-BB05B68D58FC

Q37570408-6911985D-803E-4B64-BAB6-9F8022480158

Q37570408-6CDC4AED-E988-4BA4-8590-A61619EBB69C

Q37570408-7859C147-CA49-4411-BC4B-9EC8570B2293

Q37570408-7B8B2110-4069-4CED-9609-04F4D9A41A11

Q37570408-85618D74-1FEF-4330-BD02-CFA62C35FA17

Q37570408-90165F2D-B900-4147-A1D3-A439088C6766

Q37570408-A6CADB55-22F6-450B-8ECB-CB8B7A1033BA

P304

Q37570408-4447F003-48D7-434C-BF8E-E1CE667E1323

P31

Q37570408-22C85016-CD68-48B5-8D0E-80848EB652CB

P356

Q37570408-45255A26-C345-45F6-9953-EF51EE711758

P407

Q37570408-2FC9A58A-C404-4726-B9C5-FE36063821D3

P433

Q37570408-692937C8-FB9A-48DA-9349-3F2AFB50A038

P478

Q37570408-A712ACA9-65C8-42DF-A199-0076F2A30B95

P577

Q37570408-20F04797-6DD9-434B-B337-9F97A7233154

P698

Q37570408-6D787D62-AD7D-4338-A0FA-A991BB4B9CFF

P921

Q37570408-EF794ABE-7F33-4D89-AE55-E2FF171FDCFA

P932

Q37570408-F3464D89-6996-47EF-9BE5-0385D8DB09B2

P356

JCO.2013.49.8808

P1433

Journal of Clinical Oncology

P1476

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

@en

P2093

Alexia Iasonos

http://www.w3.org/2001/XMLSchema#string

Anne A Eaton

http://www.w3.org/2001/XMLSchema#string

David M Hyman

http://www.w3.org/2001/XMLSchema#string

David R Spriggs

http://www.w3.org/2001/XMLSchema#string

Erika G Pamer

http://www.w3.org/2001/XMLSchema#string

Gary L Smith

http://www.w3.org/2001/XMLSchema#string

Martee L Hensley

http://www.w3.org/2001/XMLSchema#string

Mrinal M Gounder

http://www.w3.org/2001/XMLSchema#string

Percy Ivy

http://www.w3.org/2001/XMLSchema#string

P2860

Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital.

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.

How to build and interpret a nomogram for cancer prognosis.

Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models.

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.

P304

519-526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.49.8808

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24419130

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3918535

http://www.w3.org/2001/XMLSchema#string